The Precision Peptide Company Announces Release of The Human Upgrade with Dave Asprey Episode Featuring Chief Scientific Officer Justin Kirkland

About this update from Precision Peptide Company Inc

Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that the previously announced episode of The Human Upgrade with Dave Asprey featuring Justin Kirkland, Chief Scientific Officer of the Company, is now available. The episode is live on Apple Podcasts, Spotify, YouTube, and at daveasprey.com. The Human Upgrade, hosted by Dave Asprey, is a leading platform in the biohacking, longevity, and human performance space, built over more than a decade of conversations on health optimization and emerging science. In a wide-ranging conversation, Asprey and Kirkland discuss why so much of what is sold online is not what it claims to be, and what thirty years of making peptides teaches you about telling the difference. Kirkland walks through the part most consumers never see: why a peptide that looks flawless on a standard lab test can still be carrying a manufacturing residue that does real harm, and the additional purification step that addresses it. He explains why "American-made" often is not, and what the Company does differently by performing the chemical synthesis itself in the United States, building each peptide one amino acid at a time. And he gets into the delivery question everyone in the category is chasing, including the Company's work on needle-free microneedle patches and the analytical results behind its first production run. Along the way the two cover the range of peptides people actually ask about, how to separate credible science from marketing hype, and why "it didn't work for me" almost never means what people think it means. Justin Kirkland, Chief Scientific Officer of The Precision Peptide Company, commented: "It was a pleasure to sit down with Dave and go through the science properly, why manufacturing and quality control matter, and what credible innovation in peptide delivery actually looks like. Dave's audience cares about the science, and that is exactly the audience Precision was built to serve." Pratap Sandhu, CEO of The Precision Peptide Company, added: "It was great to hear Justin and Dave's conversation. This episode follows closely on our appearance at the BE...

View stock analysis, news, and events for Precision Peptide Company Inc